Malaria, the world’s No. 1 insect-borne infectious disease, is always asked in the immunization form before international students arriving in America.

This is an important step in the U.S. international student insurance (aka 美国留学生 保险) enrollment procedure, and it is more significant than purchasing F-1 international student medical insurance (aka 留学生 医疗保险) and/or J-1 insurance (aka j1 保险) if you are a visiting scholar. The careful medical background inquiry demonstrates the school’s responsibility and equal care to every person.

After graduation, many international students are fortunately given work offers in the United States. During their OPT period the health insurance (aka opt期间保险) is up to each individual. They are given a list of health insurance recommendations (aka 医疗保险推荐), but whether to purchase depends on the person’s preference.

Some choose to waive American university insurance (aka waive 美国大学保险), others prefer school plans. There is no correct or wrong of either choice, if eventually students have insurance since Malaria does not become extinct up till now. Scientists have been putting endeavor in fighting Malaria for decades. In 2005, the World Health Organization (WHO) recommended Artemisinin-based Combination Therapies as the most effective malaria treatment available.

Today, artemisinin is also used to treat other diseases including bilharzia, and some clinical trials for various cancers use artemisinin as well, according to Bouzidi.

“China maybe has to start finding rationales to show the efficacy and the safety of some TCM products, at least the lead products. And that would be a good start,” he said.

In March, China established the Centre for Evidence-based Chinese Medicine at the Beijing University of Chinese Medicine, first of its kind in the world, which was seen as a major step to respond to doubts with clinical evidence, according to Liu Jianping, director of the center.

As a biopharmaceutical entrepreneur, Bouzidi is confident about the future of TCM products tapping into the international market.

“With the right dose here, with the right clinical trials, any medicine showing its efficacy and safety will be used, especially if you’re talking about unmet medical needs or affordable medicine,” said Bouzidi.

China has signed specialized TCM cooperation agreements with over 40 countries, regions and organizations, built a group of TCM centers in countries and regions along the routes of the Belt and Road and opened hundreds of TCM institutes in more than 30 countries and regions.